China smartphone shipments slumped in June on inventory overhang: Jefferies
On Thursday, Deutsche Bank adjusted its outlook on Teladoc Health Inc. (NYSE:TDOC), reducing the price target from $15 to $10 while maintaining a Hold rating on the stock. This move comes as Teladoc, a virtual healthcare company, reported its second-quarter results and made the decision to withdraw its 2024 and long-term guidance for its BetterHelp segment, which is currently facing challenges.
Teladoc's recent financial disclosure revealed a slowdown in its core primary care business and a period of transition for its BetterHelp behavioral health segment. The company anticipates the possibility of a double-digit contraction in the BetterHelp segment towards the latter half of the year, citing high advertising spending and customer acquisition costs, which are expected to rise during the presidential election year.
In an unprecedented move, Teladoc provided partial guidance for the coming year, offering projections for its primary care business but retracting them for BetterHelp. The company's management, during the earnings call, expressed that they are assessing all aspects of the business and its strategic direction. This includes considering various options for the behavioral segment, with the potential of reorganization or divestiture being hinted at in response to an inquiry about selling off the business.
In other recent news, Teladoc Health Inc. has seen a series of adjustments in its price targets by various firms following its second-quarter earnings report. Deutsche Bank, TD Cowen, and RBC Capital Markets have all reduced their price targets for the company due to challenges in its BetterHelp segment and increasing customer acquisition costs. Despite surpassing adjusted EBITDA expectations, Teladoc has experienced a slowdown in its core primary care business and anticipates a potential contraction in the BetterHelp segment.
Citi also adjusted its outlook on Teladoc, reducing the price target while maintaining a neutral stance. The firm expressed concerns about potential revenue shortfalls and the declining membership in BetterHelp. Meanwhile, TD Cowen maintained its buy rating for Teladoc, emphasizing the company's potential to further integrate into the healthcare system. Barclays reiterated its overweight rating, highlighting the extensive experience of the new CEO, Chuck Divita. These are among the recent developments for Teladoc as the company navigates its current challenges and growth phase.
InvestingPro Insights
As Teladoc Health Inc. (NYSE:TDOC) navigates through its current challenges, particularly with its BetterHelp segment, it is important to consider the company's financial health and market performance. According to InvestingPro data, Teladoc has a market capitalization of approximately $1.45 billion and a notably high gross profit margin of 70.81% over the last twelve months as of Q1 2024. Despite this, the company has not been profitable during the same period, with an operating income margin of -8.57% and an EBITDA growth of 465.8%, which indicates some underlying efficiency in reducing operating losses.
InvestingPro Tips suggest that Teladoc's valuation implies a strong free cash flow yield, and the stock is trading near its 52-week low, which might attract investors looking for potential value. However, analysts are not expecting the company to be profitable this year, and the stock has experienced a significant decline over the last six months, with a price total return of -52.47%. These insights highlight the volatility and the speculative nature of the investment at this time. For those interested in a deeper analysis, there are additional InvestingPro Tips available, which can be accessed for Teladoc at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.